Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Next Previous
Trial Profile

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Stem cell mobilisation
  • Focus Pharmacodynamics

    • Most Recent Events

    • 21 Sep 2018 Status hs been changed to discontinued.
    • 18 Sep 2018 Status changed from recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top